Buprenorphine ( DrugBank: Buprenorphine )

2 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	3
70	Spinal stenosis	1

46. Malignant rheumatoid arthritis

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-TCS-14004252	2014-03-04	2014-02-12	A multicenter study for the evaluation of efficacy & safety of buprenorphine transdermal patch (Norspan or Sovenor transdermal patch) in patients with non-malignant pain of moderate to severe intensity due to osteoarthritis, rheumatoid arthritis, lower back pain and joint/muscle pain, when an opioid	A multicenter study for the evaluation of efficacy & safety of buprenorphine transdermal patch (Norspan or Sovenor transdermal patch) in patients with non-malignant pain of moderate to severe intensity due to osteoarthritis, rheumatoid arthritis, lower back pain and joint/muscle pain, when an opioid	osteoarthritis, rheumatoid arthritis, lower back pain, joint/muscle pain	case series:Norspan 5mg patch (1 patch per week), and the dose can be titrated up to maximum 40mg patch in the titration period (maximun 42 days). Patient will then be using the optimum dosage for 11 weeks, and follow-up for another 2 weeks after treatment period, maximum 19 weeks;	The Chinese University of Hong Kong	NULL	Pending	18	80	Both	case series:15;	I (Phase 1 study)	NULL
2	NCT02519387 (ClinicalTrials.gov)	July 2013	15/7/2015	Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate Intensity	Multicentre Study for Evaluation of the Efficacy and Safety of Buprenorphine Transdermal Patch (SOVENOR®) 5mg and 10mg in Patients With Non-malignant Pain of Moderate Intensity Due to Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain and Joint/Muscle Pain, When an Opioid is Necessary for Obtaining Adequate Analgesia	Osteoarthritis;Rheumatoid Arthritis;Lower Back Pain;Joint Pain;Muscle Pain	Drug: Buprenorphine Transdermal Patch	Mundipharma Pharmaceuticals Sdn. Bhd.	NULL	Completed	40 Years	N/A	All	78	Phase 4	Malaysia
3	NCT01961271 (ClinicalTrials.gov)	June 2013	7/10/2013	Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain	Multicentre Study To Evaluate Efficacy And Safety Of Buprenorphine Transdermal Patch (Norspan) In Chronic Non-Malignant Pain Of Moderate To Severe Intensity Due To Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain And Joint / Muscle Pain, When Opioid Is Needed For Analgesia	Osteoarthritis;Rheumatoid Arthritis;Lower Back Pain;Joint Pain;Muscle Pain	Drug: Buprenorphine transdermal patch	Mundipharma Pte Ltd.	Mundipharma Korea Ltd;Mundipharma (Hong Kong) Ltd;Mundipharma Distribution GmBH (Philippine Branch)	Completed	18 Years	80 Years	All	114	Phase 4	Hong Kong;Korea, Republic of;Philippines

70. Spinal stenosis

Clinical trials : 95 / Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02416804 (ClinicalTrials.gov)	January 2015	10/4/2015	Postoperative Analgesia With Buprenorphine for Postoperative Pain Control and Quality of Life After Spinal Surgery	Postoperative Analgesia With Buprenorphine Transdermal System (BTDS) Versus Tramadol for Postoperative Pain Control and Quality of Life After Spinal Surgery	Spinal Stenosis;Pain, Postoperative	Drug: Buprenorphine;Drug: Tramadol	Seoul National University Hospital	NULL	Completed	20 Years	N/A	All	69	Phase 4	Korea, Republic of